Dose-ranging activity of the newly registered antituberculosis drug bedaquiline (TMC207)

作者：Grosset Jacques H^*; Ammerman Nicole C

来源：Expert Review of Anti-Infective Therapy, 2013, 11(7): 649-651.

DOI：10.1586/14787210.2013.811848

• antimicrobial activity
• bedaquiline
• dose ranging
• early bactericidal activity
• loading doses
• tuberculosis treatment

Evaluation of: Diacon AH, Dawson R, Von Groote-Bidlingmaier F et al. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother. 57(5), 2199-2203 (2013). During the past decade considerable efforts have been made to develop and register new anti-TB drugs, making them available for patients in need. Bedaquiline (BDQ), approved by the US FDA in December 2012, is the first new anti-TB drug available for treatment of this disease since rifampicin became available in 1967. BDQ has the peculiarity of being a drug with a very long half-life and potent antimicrobial activity that becomes noticeable only after the first 4days of treatment. Consequently, Diacon et al. have conducted a 14-day dose-ranging study aimed at assessing the early bactericidal activity of BDQ in TB patients who received loading doses of the drug during the first 2days of treatment. The loading doses partially overcame the delayed antimicrobial activity only in patients treated daily with as much as 400mg.

• 出版日期2013-7